查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2126379

甲狀腺癌診斷市場－策略分析與預測（2026-2035）

Thyroid Cancer Diagnostics Market - Strategic Insights and Forecasts (2026-2035)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計甲狀腺癌診斷市場將從 2026 年的 47.5 億美元成長到 2035 年的 105.4 億美元，複合年成長率為 9.3%。

甲狀腺癌診斷市場正經歷重大變革，其驅動力源自於精準腫瘤學、分子風險分層和個人化治療策略的模式轉移。這一市場演變的特點是，人們日益認知到，準確的診斷和分子層面的特徵分析對於最佳化患者管理、減少不必要的手術以及實現標靶治療的選擇至關重要。次世代定序、基因表現分析和液態生物檢體等先進分子技術的融合，使得甲狀腺癌的檢測和風險評估能夠更快、更準確、更全面。隨著全球甲狀腺癌發生率的持續上升，世界各地的醫療系統都在不斷提升其診斷能力。隨著對分子診斷試劑盒、人工智慧驅動的細胞病理學和伴隨診斷的大量投資，甲狀腺癌診斷正逐漸成為內分泌腫瘤學和精準醫學的關鍵組成部分。

市場促進因素

  • 全球甲狀腺癌發生率的上升是推動甲狀腺癌診斷市場發展的主要動力。日益加重的疾病負擔促使全球對基於精準生物標記的早期診斷、先進分子檢測和精準腫瘤學解決方案的需求不斷成長。醫療機構正在拓展其診斷能力，以支持早期發現和個人化治療策略。這種需求推動了對各種診斷模式產品的需求，並永續地擴大了甲狀腺癌診斷的應用。次世代定序和基因組分析技術的日益普及，透過提高診斷準確性、提供個人化治療方案以及促進醫療系統內的臨床決策，進一步加速了市場成長。精準醫療需要全面的基因組特徵分析來指導標靶治療決策。醫療機構正在擴展分子檢測項目，以支持個人化治療策略。診斷設備製造商正在開發基因組分析解決方案，以滿足不斷成長的需求。人們對早期癌症檢測意識的提高，推動了常規甲狀腺篩檢的發展，並促進了影像學、細胞病理學和分子診斷技術在全球範圍內的應用。公共衛生宣傳活動提高了篩檢參與率和早期發現率。醫療系統正在擴大診斷服務和技術的覆蓋範圍。數位病理學、人工智慧和伴隨診斷技術的持續進步正在提高工作流程效率、診斷可靠性和病患管理效果。技術創新正在提高診斷準確性並減少不必要的檢查。醫療機構正在採用人工智慧驅動的診斷技術來提高效率和一致性。診斷設備製造商正在開發先進的平台以滿足不斷成長的需求。

市場限制因素

  • 分子診斷檢測和基因測序的高成本限制了這些技術的廣泛應用，尤其是在中低收入國家的醫療保健市場。先進技術所需的大量資金投入對小規模的醫療機構和發展中地區構成障礙。部分地區先進基因組診斷的保險覆蓋範圍有限，限制了病患的就醫途徑，並延緩了精準腫瘤學技術的應用。保險覆蓋範圍的區域差異給診斷服務提供者帶來不確定性，並限制了患者的就醫途徑。熟練的分子病理學家和專業實驗室技術人員的短缺影響了診斷能力、結果準確性和先進檢測方法的應用。專業人員的匱乏降低了診斷能力和擴充性。嚴格的法規核准要求增加了創新甲狀腺診斷技術的研發時間、合規成本和商業化難度。

對技術和測試方法的深入了解

  • 技術發展趨勢的特徵是分子診斷、基因組分析和人工智慧平台的重要性日益凸顯。細針穿刺切片檢查因其診斷準確率高且創傷小，仍是疑似甲狀腺結節初步評估的黃金標準。免疫組織化學有助於腫瘤的定性和鑑別診斷。基於PCR的檢測能夠發現基因突變。 NGS技術憑藉其全面的基因組分析能力正經歷快速成長。基因表現譜分析擴大用於改善風險分層並減少不必要的甲狀腺手術。細分市場分析顯示，影像診斷佔據了很大佔有率，因為超音波仍然是評估甲狀腺結節和進行風險評估的主要工具。細胞病理學透過基於細針穿刺活體組織切片的診斷繼續發揮核心作用。分子診斷是成長最快的細分市場，這主要得益於基因組分析和精準腫瘤學的日益普及。由於BRAF基因突變與乳頭狀甲狀腺癌密切相關，且在製定治療策略中發揮關鍵作用，因此BRAF基因突變檢測在生物標記領域佔據最大佔有率。 RAS基因突變分析有助於診斷具有濾泡模式的甲狀腺病變。 RET基因突變檢測在精準腫瘤學和標靶治療選擇中日益重要。甲狀腺結節的評估是一個重要的應用領域，癌症診斷和風險分層正經歷快速成長。醫院和診斷檢查室是主要的終端使用者群體，癌症中心和學術研究機構也不斷擴展其診斷能力。人工智慧的應用日益重要，因為它有助於提高診斷效率、實現工作流程自動化，並增強對觀察解讀的一致性。

競爭格局與策略展望

  • 競爭格局包括成熟的診斷和生命科學公司，以及專注於分子診斷、內分泌和精準腫瘤學的供應商。羅氏開發分子診斷、伴隨診斷、組織學診斷和精準腫瘤學解決方案，以支持甲狀腺癌的診斷和標靶治療選擇。賽默飛世爾科技提供PCR技術、定序平台、分子診斷和精準腫瘤學解決方案，以支援甲狀腺癌篩檢。丹納赫提供基因組技術、分子診斷、檢查室自動化和精準醫療解決方案，以支持腫瘤診斷。安捷倫專注於病理解決方案、免疫組織化學檢測、基因組技術和伴隨診斷，以支持甲狀腺癌診斷。 Illumina是領先的NGS平台供應商，其平台可實現甲狀腺癌的全面基因組分析和生物標記發現。凱傑開發分子診斷檢測、PCR技術、樣本製備系統和伴隨診斷，以支持個人化癌症治療。雅培提供免疫檢測、臨床化學系統、分子診斷和臨床實驗室解決方案，以支持腫瘤診斷。西門子醫療開發先進的影像系統、臨床實驗室診斷、人工智慧驅動的醫療技術和數位化診斷解決方案。兩家公司正透過在分子診斷試劑盒、液態生物檢體和人工智慧平台方面的創新來擴展產品系列。在伴隨診斷開發和精準腫瘤學解決方案需求的推動下，診斷設備製造商、製藥公司和研究機構之間的策略合作日益增加。近期的一些重要進展包括：Guardant Health增強了固體癌的基因組分析能力並擴展了液態生物檢體產品組合；Verasite透過不斷擴展甲狀腺疾病的分子診斷應用，強化了其基因組檢測產品組合；羅氏增強了支持精準腫瘤學的伴隨診斷解決方案；以及Illumina擴展了用於全面腫瘤基因組分析的NGS應用。

簡明結論

  • 受甲狀腺癌發病率上升、技術創新和精準醫療整合的推動，甲狀腺癌診斷市場預計將持續成長。從傳統診斷方法向分子和基因組策略的轉變，標誌著內分泌腫瘤學領域的根本性變革。儘管高成本、有限的保險報銷和人才短缺等挑戰依然存在，但對技術、夥伴關係和臨床檢驗的策略性投資正為市場領導提供持續的競爭優勢。長期市場前景仍然樂觀，甲狀腺癌診斷將發展成為精準腫瘤學的關鍵組成部分，在全球醫療保健系統中支持早期檢測、風險分層、治療方案選擇和改善患者預後。

本報告的主要益處：

  • 深入分析：詳細分析涵蓋各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業。
  • 競爭格局：我們將了解主要公司的策略部署，並確定最佳的市場進入方式。
  • 市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
  • 實用建議：我們支援制定策略決策，以開發新的收入來源。
  • 適用於廣泛的使用者群體：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

你用它來做什麼？

    產業和市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範和影響、新產品開發以及競爭影響。

分析範圍

  • 歷史資料（2021-2024 年）、基準年（2025 年）和預測資料（2026-2035 年）
  • 成長機會、挑戰、供應鏈前景、法規結構、顧客行為和趨勢分析。
  • 競爭對手定位、策略和市場佔有率分析
  • 營收成長率及預測分析：依業務板塊及地區（國家）分類
  • 企業概況（策略、產品、財務資訊、關鍵趨勢等）

目錄

第1章執行摘要

  • 市場概述
  • 主要分析結果
  • 分析師意見
  • 策略建議

第2章 分析方法

  • 分析設計
  • 資料收集和分析方法
  • 市場規模估算
  • 預測模型
  • 先決條件和限制

第3章：全球甲狀腺癌診斷市場：概述、市場規模與預測

  • 市場定義和範圍
  • 行業概覽
  • 疾病進展和當前診斷狀態
  • 主要市場趨勢
  • 實際成果值市場規模分析
  • 市場預測
  • 疾病盛行率分析
  • 已確診患者族群的分析
  • 對所進行的甲狀腺癌診斷測試數量進行分析。
  • 患者診斷路徑分析

第4章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰

第5章 行業情勢

  • 產業價值鏈分析
  • 定價分析
  • 還款狀態

第6章：創新趨勢

  • 新興技術
  • 產品創新
  • 分子診斷試劑盒
  • 人工智慧在甲狀腺結節評估的應用
  • 基因生物標記的開發
  • 液態生物檢體技術
  • 技術藍圖

第7章 監理情勢

  • 法律規範
  • 核准流程
  • 合規要求

第8章：全球甲狀腺癌診斷市場：展望分析

  • 分析：按診斷方式
    • 診斷影像
    • 細胞病理學
    • 分子診斷
    • 組織病理學
  • 分析：按技術
    • 細針穿刺切片檢查（FNA）
    • 免疫組織化學（IHC）
    • 聚合酵素鏈鎖反應（PCR）
    • 次世代定序（NGS）
    • 基因表現分析
  • 分析：透過生物標記
    • BRAF突變
    • RAS突變
    • RET基因突變
    • TERT啟動子突變
    • 其他生物標記
  • 分析：透過臨床應用
    • 甲狀腺結節的評估
    • 癌症診斷
    • 風險分層
    • 治療方案
    • 疾病監測

第9章 全球甲狀腺癌診斷市場：細分市場分析

  • 依產品
    • 裝置
    • 試劑和耗材
    • 軟體
  • 透過技術
    • 細針穿刺切片檢查（FNA）
    • 免疫組織化學（IHC）
    • 聚合酵素鏈鎖反應（PCR）
    • 次世代定序（NGS）
    • 基因表現分析
    • 其他技術
  • 最終用戶
    • 醫院
    • 診斷檢查室
    • 癌症中心
    • 學術研究機構

第10章：全球甲狀腺癌診斷市場：區域分析

  • 北美洲
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東和非洲

第11章 全球甲狀腺癌診斷市場：國別分析

  • 美國
  • 加拿大
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 日本
  • 中國
  • 韓國
  • 印度
  • 澳洲
  • 巴西
  • 墨西哥
  • 沙烏地阿拉伯
  • 南非

第12章 競爭格局

  • 市佔率分析
  • 策略趨勢
  • 企業合併、商業夥伴關係和合作
  • 新產品發布

第13章：公司簡介

  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Illumina, Inc.
  • QIAGEN NV
  • Abbott Laboratories
  • Siemens Healthineers AG
  • Bio-Rad Laboratories, Inc.
  • bioMerieux
  • Veracyte, Inc.
  • Exact Sciences Corporation
  • Guardant Health, Inc.
  • Leica Biosystems
  • Fujifilm Holdings Corporation

第14章：全球甲狀腺癌診斷市場：商業預測分析

第15章 投資與資金籌措分析

  • 創業投資趨勢
  • 政府資金
  • 研發投資

第16章：未來展望

  • 主要成長機遇
  • 未來產業趨勢
簡介目錄
Product Code: KSI-009091

The Thyroid Cancer Diagnostics Market is set to reach USD 10.54 billion in 2035, growing at a CAGR of 9.3 % from USD 4.75 billion in 2026.

The thyroid cancer diagnostics market is undergoing significant transformation driven by the paradigm shift toward precision oncology, molecular risk stratification, and personalized treatment strategies. The market's evolution is characterized by the growing recognition that accurate diagnosis and molecular characterization are essential for optimizing patient management, reducing unnecessary surgeries, and enabling targeted therapy selection. The convergence of advanced molecular technologies, including next-generation sequencing, gene expression profiling, and liquid biopsy, is enabling faster, more accurate, and increasingly comprehensive thyroid cancer detection and risk assessment. Healthcare systems worldwide are expanding diagnostic capabilities as thyroid cancer incidence continues to rise globally. The market is witnessing significant investment in molecular diagnostic panels, AI-assisted cytopathology, and companion diagnostics, positioning thyroid cancer diagnostics as a critical component of endocrine oncology and precision medicine.

Market Drivers

  • The rising global thyroid cancer incidence represents the primary driver for the thyroid cancer diagnostics market. Increasing disease burden creates demand for early diagnosis, advanced molecular testing, and accurate biomarker-based precision oncology solutions worldwide. Healthcare providers are expanding diagnostic capacity to support early detection and personalized treatment strategies. This requirement strengthens demand for diagnostic products across all modalities, resulting in sustained growth in thyroid cancer diagnostic utilization. The growing adoption of next-generation sequencing and genomic profiling is further accelerating market growth through improved diagnostic accuracy, personalized treatment selection, and clinical decision-making across healthcare systems. Precision medicine requires comprehensive genomic characterization to guide targeted therapy decisions. Healthcare providers are expanding molecular testing programs to support personalized treatment strategies. Diagnostic manufacturers are developing genomic profiling solutions to capture growing demand. Increasing awareness of early cancer detection encourages routine thyroid screening, boosting utilization of imaging, cytopathology, and molecular diagnostic technologies globally. Public health campaigns are increasing screening participation and early detection. Healthcare systems are expanding access to diagnostic services and technologies. Continuous advancements in digital pathology, artificial intelligence, and companion diagnostics enhance workflow efficiency, diagnostic confidence, and patient management outcomes. Technological innovation is improving diagnostic accuracy and reducing unnecessary procedures. Healthcare providers are adopting AI-assisted diagnostics to improve efficiency and consistency. Diagnostic manufacturers are developing advanced platforms to capture growing demand.

Market Restraints

  • High costs of molecular diagnostic tests and genomic sequencing limit widespread adoption, particularly across low- and middle-income healthcare markets. The significant financial investment required for advanced technologies creates barriers for smaller facilities and developing regions. Limited reimbursement coverage for advanced genomic diagnostics restricts patient access and slows adoption of precision oncology technologies in several regions. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Shortage of skilled molecular pathologists and specialized laboratory professionals affects diagnostic capacity, interpretation accuracy, and implementation of advanced testing. The limited availability of specialized personnel reduces diagnostic capacity and scalability. Stringent regulatory approval requirements increase development timelines, compliance costs, and commercialization challenges for innovative thyroid diagnostic technologies.

Technology and Modality Insights

  • The technology landscape is characterized by the growing importance of molecular diagnostics, genomic profiling, and AI-enabled platforms. Fine needle aspiration remains the gold standard for initial evaluation of suspicious thyroid nodules due to its high diagnostic accuracy and minimally invasive nature. Immunohistochemistry supports tumor characterization and differential diagnosis. PCR-based assays enable mutation detection. NGS is experiencing rapid growth through comprehensive genomic profiling. Gene expression profiling is increasingly utilized to improve risk stratification and reduce unnecessary thyroid surgeries. The segment analysis reveals that imaging diagnostics account for a significant share as ultrasound remains the primary tool for thyroid nodule evaluation and risk assessment. Cytopathology continues to play a central role through FNA-based diagnosis. Molecular diagnostics represent the fastest-growing segment owing to increasing adoption of genomic profiling and precision oncology. BRAF mutation testing represents the largest biomarker segment because of its strong association with papillary thyroid carcinoma and therapeutic decision-making. RAS mutation analysis supports diagnosis of follicular-patterned thyroid lesions. RET gene alteration testing is becoming increasingly important for precision oncology and targeted therapy selection. Thyroid nodule evaluation represents a critical application, with cancer diagnosis and risk stratification experiencing rapid growth. Hospitals and diagnostic laboratories represent the leading end-user segments, with cancer centers and academic research institutes expanding diagnostic capabilities. The integration of AI is becoming increasingly important as AI improves diagnostic efficiency, workflow automation, and interpretation consistency.

Competitive and Strategic Outlook

  • The competitive landscape features established diagnostics and life science companies alongside specialized molecular, endocrine, and precision oncology providers. Roche develops molecular diagnostics, companion diagnostics, tissue diagnostics, and precision oncology solutions supporting thyroid cancer diagnosis and targeted treatment selection. Thermo Fisher Scientific provides PCR technologies, sequencing platforms, molecular diagnostics, and precision oncology solutions supporting thyroid cancer testing. Danaher offers genomics technologies, molecular diagnostics, laboratory automation, and precision medicine solutions supporting oncology diagnostics. Agilent specializes in pathology solutions, immunohistochemistry assays, genomic technologies, and companion diagnostics supporting thyroid cancer diagnosis. Illumina is a leading provider of NGS platforms enabling comprehensive genomic profiling and biomarker discovery for thyroid cancer. QIAGEN develops molecular diagnostic assays, PCR technologies, sample preparation systems, and companion diagnostics supporting personalized oncology. Abbott provides immunoassays, clinical chemistry systems, molecular diagnostics, and laboratory testing solutions supporting oncology diagnostics. Siemens Healthineers develops advanced imaging systems, laboratory diagnostics, AI-enabled healthcare technologies, and digital diagnostic solutions. Companies are pursuing product portfolio expansion through innovation in molecular diagnostic panels, liquid biopsy, and AI-enabled platforms. Strategic collaborations between diagnostic manufacturers, pharmaceutical companies, and research institutions are increasing, driven by the need for companion diagnostic development and precision oncology solutions. Recent key developments include Guardant Health expanding its liquid biopsy portfolio with enhanced genomic profiling capabilities for solid tumors. Veracyte advanced its genomic testing portfolio through continued expansion of molecular diagnostic applications for thyroid disease. Roche introduced enhanced companion diagnostic solutions supporting precision oncology. Illumina expanded NGS applications for comprehensive oncology genomic profiling.

Short Conclusion

  • The thyroid cancer diagnostics market is positioned for sustained growth driven by the convergence of rising disease incidence, technological innovation, and precision medicine. The transition from conventional diagnostic approaches toward integrated molecular and genomic strategies represents a fundamental shift in endocrine oncology. While challenges related to high costs, reimbursement limitations, and workforce shortages persist, strategic investments in technology, partnerships, and clinical validation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with thyroid cancer diagnostics evolving into a critical component of precision oncology, supporting early detection, risk stratification, treatment selection, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

  • Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
  • Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
  • Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
  • Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
  • Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

  • Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

  • Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
  • Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
  • Competitive positioning, strategies, and market share evaluation, and trade analysis
  • Revenue growth and forecast assessment across segments and regions
  • Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Market Snapshot
  • 1.2 Key Findings
  • 1.3 Analyst Insights
  • 1.4 Strategic Recommendations

2. Research Methodology

  • 2.1 Research Design
  • 2.2 Data Collection Methodology
  • 2.3 Market Size Estimation
  • 2.4 Forecasting Model
  • 2.5 Assumptions & Limitations

3. Global Thyroid Cancer Diagnostics Market Overview, Size & Forecast

  • 3.1 Market Definition & Scope
  • 3.2 Disease Overview
  • 3.3 Disease Evolution and Diagnostic Landscape
  • 3.4 Key Market Trends
  • 3.5 Historical Market Size Analysis (2021-2025)
  • 3.6 Market Forecast (2026-2035)
  • 3.7 Disease Prevalence Analysis
  • 3.8 Diagnosed Patient Population Analysis
  • 3.9 Thyroid Cancer Diagnostic Testing Volume Analysis
  • 3.10 Patient Diagnostic Pathway Analysis

4. Market Dynamics

  • 4.1 Market Drivers
  • 4.2 Market Restraints
  • 4.3 Market Opportunities
  • 4.4 Market Challenges

5. Industry Landscape

  • 5.1 Industry Value Chain Analysis
  • 5.2 Pricing Analysis
  • 5.3 Reimbursement Landscape

6. Innovation Landscape

  • 6.1 Emerging Technologies
  • 6.2 Product Innovation
  • 6.3 Molecular Diagnostic Panels
  • 6.4 Artificial Intelligence in Thyroid Nodule Assessment
  • 6.5 Genomic Biomarker Development
  • 6.6 Liquid Biopsy Technologies
  • 6.7 Technology Roadmap

7. Regulatory Landscape

  • 7.1 Regulatory Framework
  • 7.2 Approval Pathways
  • 7.3 Compliance Requirements

8. Global Thyroid Cancer Diagnostics Market Landscape Analysis

  • 8.1 Analysis by Diagnostic Modality
    • 8.1.1 Imaging Diagnostics
    • 8.1.2 Cytopathology
    • 8.1.3 Molecular Diagnostics
    • 8.1.4 Histopathology
  • 8.2 Analysis by Technology
    • 8.2.1 Fine Needle Aspiration (FNA)
    • 8.2.2 Immunohistochemistry (IHC)
    • 8.2.3 Polymerase Chain Reaction (PCR)
    • 8.2.4 Next-Generation Sequencing (NGS)
    • 8.2.5 Gene Expression Profiling
  • 8.3 Analysis by Biomarker
    • 8.3.1 BRAF Mutation
    • 8.3.2 RAS Mutation
    • 8.3.3 RET Gene Alterations
    • 8.3.4 TERT Promoter Mutation
    • 8.3.5 Other Biomarkers
  • 8.4 Analysis by Clinical Application
    • 8.4.1 Thyroid Nodule Evaluation
    • 8.4.2 Cancer Diagnosis
    • 8.4.3 Risk Stratification
    • 8.4.4 Treatment Selection
    • 8.4.5 Disease Monitoring

9. Global Thyroid Cancer Diagnostics Market Segment Analysis (2021-2035)

  • 9.1 By Product
    • 9.1.1 Instruments
    • 9.1.2 Reagents & Consumables
    • 9.1.3 Software
  • 9.2 By Technology
    • 9.2.1 Fine Needle Aspiration (FNA)
    • 9.2.2 Immunohistochemistry (IHC)
    • 9.2.3 Polymerase Chain Reaction (PCR)
    • 9.2.4 Next-Generation Sequencing (NGS)
    • 9.2.5 Gene Expression Profiling
    • 9.2.6 Other Technologies
  • 9.3 By End User
    • 9.3.1 Hospitals
    • 9.3.2 Diagnostic Laboratories
    • 9.3.3 Cancer Centers
    • 9.3.4 Academic & Research Institutes

10. Global Thyroid Cancer Diagnostics Market Geographical Analysis (2021-2035)

  • 10.1 North America
  • 10.2 Europe
  • 10.3 Asia-Pacific
  • 10.4 South America
  • 10.5 Middle East & Africa

11. Global Thyroid Cancer Diagnostics Market Country Analysis (2021-2035)

  • 11.1 United States
  • 11.2 Canada
  • 11.3 Germany
  • 11.4 United Kingdom
  • 11.5 France
  • 11.6 Italy
  • 11.7 Spain
  • 11.8 Japan
  • 11.9 China
  • 11.10 South Korea
  • 11.11 India
  • 11.12 Australia
  • 11.13 Brazil
  • 11.14 Mexico
  • 11.15 Saudi Arabia
  • 11.16 South Africa

12. Competitive Landscape

  • 12.1 Market Share Analysis
  • 12.2 Strategic Developments
  • 12.3 Mergers & Acquisitions, Partnerships & Collaborations
  • 12.4 Product Launches

13. Company Profiles

  • 13.1 F. Hoffmann-La Roche Ltd.
    • 13.1.1 Company Overview
    • 13.1.2 Financials
    • 13.1.3 Product Portfolio
    • 13.1.4 Recent Developments
  • 13.2 Thermo Fisher Scientific Inc.
    • 13.2.1 Company Overview
    • 13.2.2 Financials
    • 13.2.3 Product Portfolio
    • 13.2.4 Recent Developments
  • 13.3 Danaher Corporation
    • 13.3.1 Company Overview
    • 13.3.2 Financials
    • 13.3.3 Product Portfolio
    • 13.3.4 Recent Developments
  • 13.4 Agilent Technologies, Inc.
    • 13.4.1 Company Overview
    • 13.4.2 Financials
    • 13.4.3 Product Portfolio
    • 13.4.4 Recent Developments
  • 13.5 Illumina, Inc.
    • 13.5.1 Company Overview
    • 13.5.2 Financials
    • 13.5.3 Product Portfolio
    • 13.5.4 Recent Developments
  • 13.6 QIAGEN N.V.
    • 13.6.1 Company Overview
    • 13.6.2 Financials
    • 13.6.3 Product Portfolio
    • 13.6.4 Recent Developments
  • 13.7 Abbott Laboratories
    • 13.7.1 Company Overview
    • 13.7.2 Financials
    • 13.7.3 Product Portfolio
    • 13.7.4 Recent Developments
  • 13.8 Siemens Healthineers AG
    • 13.8.1 Company Overview
    • 13.8.2 Financials
    • 13.8.3 Product Portfolio
    • 13.8.4 Recent Developments
  • 13.9 Bio-Rad Laboratories, Inc.
    • 13.9.1 Company Overview
    • 13.9.2 Financials
    • 13.9.3 Product Portfolio
    • 13.9.4 Recent Developments
  • 13.10 bioMerieux
    • 13.10.1 Company Overview
    • 13.10.2 Financials
    • 13.10.3 Product Portfolio
    • 13.10.4 Recent Developments
  • 13.11 Veracyte, Inc.
    • 13.11.1 Company Overview
    • 13.11.2 Financials
    • 13.11.3 Product Portfolio
    • 13.11.4 Recent Developments
  • 13.12 Exact Sciences Corporation
    • 13.12.1 Company Overview
    • 13.12.2 Financials
    • 13.12.3 Product Portfolio
    • 13.12.4 Recent Developments
  • 13.13 Guardant Health, Inc.
    • 13.13.1 Company Overview
    • 13.13.2 Financials
    • 13.13.3 Product Portfolio
    • 13.13.4 Recent Developments
  • 13.14 Leica Biosystems
    • 13.14.1 Company Overview
    • 13.14.2 Financials
    • 13.14.3 Product Portfolio
    • 13.14.4 Recent Developments
  • 13.15 Fujifilm Holdings Corporation
    • 13.15.1 Company Overview
    • 13.15.2 Financials
    • 13.15.3 Product Portfolio
    • 13.15.4 Recent Developments

14. Global Thyroid Cancer Diagnostics Market Commercial Forecast Analysis

  • 14.1 Fine Needle Aspiration (FNA)-Based Diagnostics
  • 14.2 Molecular Diagnostic Panels
  • 14.3 Gene Expression Classifier Tests
  • 14.4 Next-Generation Sequencing (NGS)-Based Tests
  • 14.5 Immunohistochemistry (IHC)-Based Diagnostics
  • 14.6 Liquid Biopsy Tests
  • 14.7 Imaging Diagnostics

15. Investment & Funding Analysis

  • 15.1 Venture Capital Trends
  • 15.2 Government Funding
  • 15.3 R&D Investments

16. Future Outlook

  • 16.1 Key Growth Opportunities
  • 16.2 Future Industry Trends